BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Rethinking Clinical Trials - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rethinking Clinical Trials
X-ORIGINAL-URL:https://rethinkingclinicaltrials.org
X-WR-CALDESC:Events for Rethinking Clinical Trials
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220708T130000
DTEND;TZID=America/New_York:20220708T140000
DTSTAMP:20260617T181526
CREATED:20220627T171747Z
LAST-MODIFIED:20220713T150350Z
UID:27474-1657285200-1657288800@rethinkingclinicaltrials.org
SUMMARY:Grand Rounds July 8: Results From the COVID-OUT Trial\, a Phase-3 Trial of Outpatient Treatment for COVID-19 Using Metformin\, Ivermectin\, and Fluvoxamine (Carolyn Bramante\, MD\, MPH; Thomas Murray\, PhD; Jaren Huling\, PhD)
DESCRIPTION:Speakers: \nCarolyn Bramante\, MD\, MPH\nAssistant Professor\, General Internal Medicine and Pediatrics\nCore Faculty\, Center for Pediatric Obesity Medicine\nCore Faculty\, Program for Health Disparities Research\nUniversity of Minnesota Medical School \nThomas Murray\, PhD\nAssistant Professor of Biostatistics\nDivision of Biostatistics\nUniversity of Minnesota School of Public Health \nJared Huling\, PhD\nAssistant Professor of Biostatistics\nDivision of Biostatistics\nUniversity of Minnesota School of Public Health \n  \nTopic: Results From the COVID-OUT Trial\, a Phase-3 trial of Outpatient Treatment for Covid-19 Using Metformin\, Ivermectin\, and Fluvoxamine\nDate: Friday\, July 8\, 2022\, 1:00-2:00 p.m. ET \n  \nJoin Zoom Meeting \nhttps://duke.zoom.us/j/95781921415?pwd=QlllTVd3Z0Q1S3BWT21sSjRpQ3p5Zz09 \nMeeting ID: 957 8192 1415 \nPasscode: 12345 \nClick ‘Connect to Audio”\nChoose ‘Computer Audio’ or ‘I will call in’.\nIf using the ‘call in option’\, follow the information from the dialog box that appears.\nBe certain to use the Access Code AND the Attendee ID. \nFor Audio ONLY:\nCall-in toll number (US/Canada): 1-650-479-3207\nAccess code: 2622 682 0537 \nNOTE: For Toll-free users\, the call-back (call me) services are also available.
URL:https://rethinkingclinicaltrials.org/event/grand-rounds-july-8-results-from-the-covid-out-trial-a-phase-3-trial-of-outpatient-treatment-for-covid-19-using-metformin-ivermectin-and-fluvoxamine/
CATEGORIES:Grand Rounds Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220715T130000
DTEND;TZID=America/New_York:20220715T140000
DTSTAMP:20260617T181526
CREATED:20220627T172404Z
LAST-MODIFIED:20220713T150431Z
UID:27481-1657890000-1657893600@rethinkingclinicaltrials.org
SUMMARY:Grand Rounds July 15: Overview of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Public-Private Partnership and Lessons Learned (Stacey J. Adam\, PhD)
DESCRIPTION:Speaker: \nStacey J. Adam\, PhD\nAssociate Vice President\, Research Partnerships\nFoundation for the NIH \n  \nTopic: Overview of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Public-Private Partnership and Lessons Learned\nDate: Friday\, July 15\, 2022\, 1:00-2:00 p.m. ET \n  \nMeeting Info: To check whether you have the appropriate players installed for UCF (Universal Communications Format) rich media files\, go to https://dukemed.webex.com/dukemed/systemdiagnosis.php. \nTo join the online meeting:\nGo to https://dukemed.webex.com/dukemed/j.php?MTID=m4c6e3e4827442a92338a5649cee613e6 \nClick ‘Connect to Audio”\nChoose ‘Computer Audio’ or ‘I will call in’.\nIf using the ‘call in option’\, follow the information from the dialog box that appears.\nBe certain to use the Access Code AND the Attendee ID. \nTroubleshooting:\nIf the URL above does not work\, go to dukemed.webex.com and enter:\nMeeting Number: 2622 682 0537\nMeeting Password: 12345 \nFor Audio ONLY:\nCall-in toll number (US/Canada): 1-650-479-3207\nAccess code: 2622 682 0537 \nNOTE: For Toll-free users\, the call-back (call me) services are also available.
URL:https://rethinkingclinicaltrials.org/event/grand-rounds-july-15-overview-of-accelerating-covid-19-therapeutic-interventions-and-vaccines-activ-public-private-partnership-and-lessons-learned/
CATEGORIES:Grand Rounds Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220722T130000
DTEND;TZID=America/New_York:20220722T140000
DTSTAMP:20260617T181526
CREATED:20220713T150223Z
LAST-MODIFIED:20220718T194934Z
UID:27590-1658494800-1658498400@rethinkingclinicaltrials.org
SUMMARY:Grand Rounds July 22: ACTIV-6: One Year Later and Trial Results for Ivermectin-400 and Inhaled Fluticasone (Susanna Naggie\, MD\, MHS)
DESCRIPTION:Speaker: \nSusanna Naggie\, MD\, MHS\nProfessor of Medicine\nVice Dean for Clinical Research\nDuke University School of Medicine\nInfectious Diseases Research\nDuke Clinical Research Institute \n  \nTopic: ACTIV-6: 1-year Later and Trial Results for Ivermectin-400 and Inhaled Fluticasone\nDate: Friday\, July 22\, 2022\, 1:00-2:00 p.m. ET \n  \nMeeting Info: To check whether you have the appropriate players installed for UCF (Universal Communications Format) rich media files\, go to https://dukemed.webex.com/dukemed/systemdiagnosis.php. \nTo join the online meeting:\nGo to https://dukemed.webex.com/dukemed/j.php?MTID=m4c6e3e4827442a92338a5649cee613e6 \nClick ‘Connect to Audio”\nChoose ‘Computer Audio’ or ‘I will call in’.\nIf using the ‘call in option’\, follow the information from the dialog box that appears.\nBe certain to use the Access Code AND the Attendee ID. \nTroubleshooting:\nIf the URL above does not work\, go to dukemed.webex.com and enter:\nMeeting Number: 2622 682 0537\nMeeting Password: 12345 \nFor Audio ONLY:\nCall-in toll number (US/Canada): 1-650-479-3207\nAccess code: 2622 682 0537 \nNOTE: For Toll-free users\, the call-back (call me) services are also available.
URL:https://rethinkingclinicaltrials.org/event/grand-rounds-july-22-activ-6-1-year-later-and-trial-results-for-ivermectin-400-and-inhaled-fluticasone-susanna-naggie-md-mhs/
CATEGORIES:Grand Rounds Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220729T130000
DTEND;TZID=America/New_York:20220729T140000
DTSTAMP:20260617T181526
CREATED:20220630T190844Z
LAST-MODIFIED:20220729T134101Z
UID:27512-1659099600-1659103200@rethinkingclinicaltrials.org
SUMMARY:Grand Rounds July 29: Effect of Early Treatment With Single-Dose Pegylated Interferon Lambda Among Patients With COVID-19: Results From the TOGETHER Trial (Edward Mills\, PhD\, FRCP; Jeffrey S. Glenn\, MD\, PhD)
DESCRIPTION:Speakers: \nEdward Mills\, PhD\, FRCP\nProfessor\nDepartment of Health Research Methods\, Evidence & Impact\nMcMaster University\, Canada \nJeffrey S. Glenn\, MD\, PhD\nJoseph D. Grant Professor and Professor of Microbiology and Immunology\nStanford University \nTopic: Effect of Early Treatment With Single-Dose Pegylated Interferon Lambda Among Patients With COVID-19: Results From the TOGETHER Trial\nDate: Friday\, July 29\, 2022\, 1:00-2:00 p.m. ET \nMeeting Info: To check whether you have the appropriate players installed for UCF (Universal Communications Format) rich media files\, go to https://dukemed.webex.com/dukemed/systemdiagnosis.php. \nTo join the online meeting:\nGo to https://dukemed.webex.com/dukemed/j.php?MTID=m4c6e3e4827442a92338a5649cee613e6 \nClick ‘Connect to Audio”\nChoose ‘Computer Audio’ or ‘I will call in’.\nIf using the ‘call in option’\, follow the information from the dialog box that appears.\nBe certain to use the Access Code AND the Attendee ID. \nTroubleshooting:\nIf the URL above does not work\, go to dukemed.webex.com and enter:\nMeeting Number: 2622 682 0537\nMeeting Password: 12345 \nFor Audio ONLY:\nCall-in toll number (US/Canada): 1-650-479-3207\nAccess code: 2622 682 0537 \nNOTE: For Toll-free users\, the call-back (call me) services are also available.
URL:https://rethinkingclinicaltrials.org/event/grand-rounds-july-29-effect-of-early-treatment-with-single-dose-pegylated-interferon-lambda-among-patients-with-covid-19-results-from-the-together-trial/
CATEGORIES:Grand Rounds Event
END:VEVENT
END:VCALENDAR